Therapy of relapsed/ refractory multiple myeloma with a combination of Lenalidomide plus Dexamethasone: First interim analysis of the non-interventional study “Revlimid.”

Knauf, W., Aldaoud, A., Groschek, M., Teichmann, B., Harde, J., Hasskarl, J., 2013.

Onkologie 36 (suppl. 7)(P532), 155. doi:10.1159/000356365

Studie: Revlimid-NIS; Indikation: Hämoblastosen; Jahr: 2013; Veranstaltung: DGHO; Journal: Onkologie

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com